Patients With Differentiated Thyroid Cancer Who Underwent Radioiodine Thyroid Remnant Ablation With Low-Activity 131I After Either Recombinant Human TSH or Thyroid Hormone Therapy Withdrawal Showed the Same Outcome After a 10-Year Follow-up | Zendy

Eleonora Molinaro | Zendy; Carlotta Giani | Zendy; Laura Agate | Zendy; Agnese Biagini | Zendy; Letizia Pieruzzi | Zendy; Francesca Bianchi | Zendy; Federica Brozzi | Zendy; Claudia Ceccarelli | Zendy; David Viola | Zendy; Paolo Piaggi | Zendy; Paolo Vitti | Zendy; Furio Pacini | Zendy; Rossella Elisei | Zendy

Open Access

Patients With Differentiated Thyroid Cancer Who Underwent Radioiodine Thyroid Remnant Ablation With Low-Activity 131I After Either Recombinant Human TSH or Thyroid Hormone Therapy Withdrawal Showed the Same Outcome After a 10-Year Follow-up

Author(s) -

Eleonora Molinaro,

Carlotta Giani,

Laura Agate,

Agnese Biagini,

Letizia Pieruzzi,

Francesca Bianchi,

Federica Brozzi,

Claudia Ceccarelli,

David Viola,

Paolo Piaggi,

Paolo Vitti,

Furio Pacini,

Rossella Elisei

Publication year - 2013

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2012-4137

Subject(s) - medicine , thyroid carcinoma , thyroglobulin , hormone , thyroid cancer , ablation , thyroid , thyroidectomy , urology , endocrinology , pathological , gastroenterology

No long-term follow-up data are available for differentiated thyroid carcinoma (DTC) patients prepared with either exogenous or endogenous TSH and treated with low-activity (1.1 GBq [30 mCi]) radioiodine (¹³¹I).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research